Technology
TP-317: First Stable RvE1 Drug — Patent Protection to 2048
The Stability Breakthrough
Novel pharmaceutical composition of RvE1 solves the problem blocking clinical development of resolvin drugs.
Enables Clinical Development
Functional Benefits Validated In Phase 1a Healthy Volunteer Study
